Interventional2022-12-16T17:04:01+03:00
Studies on…
sepsis and severe infections
systemic inflammatory disorders
1April, 2020

SAVE

April 1st, 2020|Tags: , |

Completed study Official Study Title suPAR-guided Anakinra treatment for Validation of the risk and Early management of severe respiratory failure by COVID-19: the SAVE open-label, non-randomized single-arm trial Brief Description SAVE is an open non-randomized clinical trial aiming to study the early treatment of patients with COVID-19 pneumonia with anakinra guided by the biomarker

1April, 2020

ESCAPE

April 1st, 2020|Tags: , |

Completed study Official Study Title Efficiency in management of organ dysfunction associated with infection by the novel SARS-Cov-2 virus through A PErsonalized immunotherapy approach Brief Description ESCAPE is an open non-randomized clinical trial aiming to the personalized therapy of patients with COVID-19. Using biomarkers, enrolled patients are receiving treatment with intravenous anakinra or intravenous

1November, 2019

INCREDIBLE-ME

November 1st, 2019|Tags: |

Ongoing study Official Study Title Gut-derived INCREtin hormones in the pathophysiology of Type 1 DiaBetes MeLlitus; Effect of Metformin treatment (the INCREDIBLE-ME trial) Brief Description INCREDIBLE-ME is a randomized clinical trial aiming to study the effect of adjunct metformin treatment to insulin monotherapy in patients with type 1 diabetes, targeting the intestinal incretin secretion.

1November, 2019

PROUD-1

November 1st, 2019|Tags: , |

Completed study Official Study Title Pulse PhotoplethysmogAaphy as an early tool for the diagnosis of sepsis thrOUgh a two-stage Development approach Brief Description PROUD-1 is an interventional trial aiming to validate the diagnostic accuracy of a new optical biosensor for the diagnosis of sepsis and for COVID-19. Details Status: Completed Study Type: Interventional

1July, 2019

LIGHT

July 1st, 2019|Tags: |

Completed study Official Study Title A double-blind, randomised, placebo-controlled clinical trial of the safety and efficacy of MABp1, a- first-in-class true human antibody targeting interleukin-1alpha, in patients with hidradenitis suppurativa not eligible for adalimumab Brief Description LIGHT is a double-blind randomized study aiming to the comparison of the efficacy of MABp1 (Bermekimab), a fully

1October, 2018

SUPERIOR

October 1st, 2018|Tags: |

Completed study Official Study Title a SUPar guided doublE-blind Randomized clinical trial of Initiation Of antibiotics foR presumed infection at the emergency department Brief Description SUPERIOR is a randomized clinical trial aiming to evaluate suPAR - guided medical intervention, consisting of early antibiotic administration at the emergency room for presumed infection and sepsis and

Go to Top